Achieve Life Sciences Q3 net loss and loss per share beat estimates

Achieve Life Sciences

10/11/2026 13:09

Overview
US pharmaceutical firm's Q3 net loss and loss per share both beat analyst expectations
Q3 operating loss narrowed, beating analyst expectations
NDA resubmission for cytisinicline on track for Q4 2026, with possible FDA approval in 2027

Outlook
Company expects NDA resubmission for cytisinicline in Q4 2026
Company anticipates potential FDA approval by end of Q2 2027
AchieveRx plans U.S. commercial launch of cytisinicline following FDA approval, if granted

Result Drivers
CLINICAL RESULTS - Co said ORCA-OL trial data showed rising quit rates and no new safety signals for cytisinicline
MANUFACTURING PROGRESS - Co completed three commercial-scale stability batches for cytisinicline, supporting NDA resubmission timeline
LEADERSHIP EXPANSION - Co expanded launch team with two senior appointments as it prepares for commercialization

Company press release: ID:nGNX15vxL2

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Loss Per Share
Beat
$0.11
$0.20 (12 Analysts)
Q3 Net Loss
Beat
$12.11 mln
$19.30 mln (9 Analysts)
Q3 Income From Operations
Beat
-$20.54 mln
-$22.79 mln (9 Analysts)
Q3 Operating Expenses
 
$20.54 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Achieve Life Sciences, Inc. is $12.50, about 84.4% NOT AVAILABLE its November 9 closing price of $6.78

Reuters Recommended Reads
Nov 9 - Canada's Xenon Pharmaceuticals posts smaller-than-expected Q3 net loss
Nov 9 - Annexon Biosciences Q3 net loss narrows on lower R&D expenses, cash runway extends to 2028
Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)